Source-grounded facts extracted from Nuvalent, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Nuvalent, Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-16 meeting.
“Proposal No. 3 — The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified, based on the following votes: For Against Abstain Broker Non-Votes 71,172,889 858 17,147 —”
Nuvalent, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-16 meeting.
“Proposal No. 2 — The compensation paid to the Company’s named executive officers was approved, on an advisory basis, based on the following votes: For Against Abstain Broker Non-Votes 68,898,711 1,786,465 17,926 487,792”
Nuvalent, Inc. shareholders approved Election of Class II directors at the 2026-06-16 meeting.
“Proposal No. 1 — The following nominees were elected as Class II directors, each to serve on the Board for a three-year term expiring at the 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified, based on the following votes: Nominee For Withheld Broker Non-Votes Michael L. Meyers, M.D., Ph.D. 57,592,636 13,110,466 487,792 Ron Squarer 70,612,828 90,274 487,792”
Nuvalent, Inc. entered into Agreement and Plan of Merger with GlaxoSmithKline LLC, Harmony Row Acquisition Co., and GSK plc valued at $124.00 per Share (effective 2026-06-09).
“On June 9, 2026, Nuvalent, Inc., a Delaware corporation (the “ Company ” or “ Nuvalent ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with GlaxoSmithKline LLC, a Delaware limited liability company (“ Parent ”), Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (“ Purchaser ”) and, solely for purposes of Section 9.14 thereof, GSK plc, a public limited company organized under the laws of England and Wales (“ Ultimate Parent ”).”
Nuvalent, Inc. reported financial results for first quarter 2026.
“Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline progress, reiterated key anticipated milestones, and reported first quarter 2026 financial results.”
Christy J. Oliger was elected as Class III director at Nuvalent, Inc..
“the Board elected Christy J. Oliger as a member of the Board, effective immediately.”
Emily Conley resigned as Director at Nuvalent, Inc..
“On June 9, 2025, Emily Conley, a member of the board of directors (the “Board”) of Nuvalent, Inc. (the “Company”), notified the Company of her decision to resign from the Board and from all committees of the Board on which she serves, effective as of the date and time of the Company’s 2025 annual meeting of stockholders.”
D. Gary Gilliland resigned as member of the board of directors at Nuvalent, Inc..
“On April 11, 2025, D. Gary Gilliland, M.D., Ph.D., a member of the board of directors (the “Board”) of Nuvalent, Inc. (the “Company”), notified the Company of his decision to resign from the Board and from all committees of the Board on which he serves, effective as of the date and time of the Company’s 2025 annual meeting of stockholders.”
Nuvalent, Inc. reported first quarter 2024 results: net income Net loss was $44.5 million for the first quarter of 2024..
“Net loss was $44.5 million for the first quarter of 2024.”
Nuvalent, Inc. reported the fourth quarter of 2023 and the year ended December 31, 2023 results: net income Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023..
“Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results”
Nuvalent, Inc. reported the quarter and year ended December 31, 2023 results: net income Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023..
“On February 27, 2024, Nuvalent, Inc. announced its financial results for the quarter and year ended December 31, 2024, and other corporate updates.”
Nuvalent, Inc. reported financial results for quarter ended September 30, 2023.
“On November 14, 2023, Nuvalent, Inc. announced its financial results for the quarter ended September 30, 2023, and other corporate updates.”
Nuvalent, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Cowen and Company, LLC, Piper Sandler & Co. and BMO Capital Markets Corp., as representatives of the several underwriters (effective 2023-10-16).
“On October 16, 2023, Nuvalent, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Cowen and Company, LLC, Piper Sandler & Co. and BMO Capital Markets Corp., as representatives of the several underwriters (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 5,357,143 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”).”
Nuvalent, Inc. reported second quarter 2023 results: net income $29.1 million, or $0.51 per share.
“Net loss for the second quarter of 2023 was $29.1 million, or $0.51 per share.”
Nuvalent, Inc.: Stockholders approved an amendment to the Third Amended and Restated Certificate of Incorporation to add officer exculpation provisions permitted under new Delaware law (effective 2023-06-15).
“At the Annual Meeting, the Company's stockholders approved an amendment to the Company's Third Amended and Restated Certificate of Incorporation”
Nuvalent, Inc. shareholders approved Approval of Amendment to Certificate of Incorporation at the 2023-06-15 meeting.
“Proposal No. 3 — The Amendment was approved, based on the following votes: For Against Abstain Broker Non-Votes 48,317,455 450,614 89 237,946”
Nuvalent, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.
“Proposal No. 2 — The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified, based on the following votes: For Against Abstain Broker Non-Votes 48,859,156 146,697 251 —”
Nuvalent, Inc. shareholders approved Election of Class II directors at the 2023-06-15 meeting.
“Proposal No. 1 — The following nominees were elected as Class II directors, each to serve on the Company’s Board of Directors for a three-year term expiring at the 2026 annual meeting of stockholders and until their respective successors have been duly elected and qualified, based on the following votes: Nominee For Withheld Broker Non-Votes Gary Gilliland, M.D., Ph.D. 35,093,835 13,674,323 237,946 Michael L. Meyers, M.D., Ph.D. 48,618,635 149,523 237,946 Joseph Pearlberg, M.D., Ph.D. 46,022,654 2,745,504 237,946 Matthew Shair, Ph.D. 47,781,329 986,829 237,946”
Nuvalent, Inc. reported the first quarter of 2023 results: net income Net loss for the first quarter of 2023 was $25.2 million, EPS $0.44 per share.
“Net loss for the first quarter of 2023 was $25.2 million, or $0.44 per share.”
Nuvalent, Inc. reported financial results for the quarter and year ended December 31, 2022.
“announced its financial results for the quarter and year ended December 31, 2023, and other corporate updates. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.”
Nuvalent, Inc. amended Amendment No. 1 to the Sales Agreement with Cowen valued at $135.0 million (effective 2022-10-31).
“On October 31, 2022, prior to the Company’s entry into the Underwriting Agreement, the Company and Cowen entered into an Amendment No. 1 to the Sales Agreement, dated as of August 10, 2022, between the Company and Cowen (the “Sales Agreement Amendment”) pursuant to which the Company may offer and sell shares of Common Stock from time to time through Cowen in an “at the market offering” (the “ATM Facility”).”
Nuvalent, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Cowen and Company, LLC, Piper Sandler & Co. and BMO Capital Markets Corp. (effective 2022-10-31).
“On October 31, 2022, Nuvalent, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Cowen and Company, LLC (“Cowen”), Piper Sandler & Co. and BMO Capital Markets Corp., as representatives of the several underwriters (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 6,865,672 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”).”
Michael L. Meyers was elected as Director at Nuvalent, Inc..
“On October 4, 2022, in accordance with the recommendation of the Nominating and Corporate Governance Committee (“NCG Committee”) of the Board of Directors (the “Board”) of Nuvalent, Inc. (the “Company”), the Board elected Michael L. Meyers, M.D., Ph.D., as a member of the Board, effective immediately.”
Anna Protopapas was elected as Chairperson of the Board at Nuvalent, Inc..
“On March 30, 2022, in accordance with the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Nuvalent, Inc. (the “Company”), the Board elected Anna Protopapas as a member of the Board, effective immediately.”
Emily Conley was elected as Director at Nuvalent, Inc..
“the Board elected Emily Conley as a member of the Board, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.